Carl Zeiss, Cellomics Collaborate in NIH Small Molecule Screening Initiative
Carl Zeiss Microimaging and Cellomics announced on July 18 their involvement in two National Institutes of Health initiatives geared towards bringing small molecule screening to basic science researchers.
Zeiss and Cellomics will be contributing products and services to the NIH Molecular Libraries Screening Centers Network and overall Molecular Libraries Initiative. MLSCN research objectives include automation for target-based and cell-based phenotypic assays, software for managing molecular library screening, and informatics tools for data management.
Cellomics offers a variety of products for cell-based drug screening, including instrumentation and informatics software. Its confocal-based flagship cellular imaging platform, ArrayScan, utilizes Zeiss’ Apotome optical sectioning technology.
Phenomix Inks Drug Discovery Deal With Genentech
San Diego-based Phenomix has signed a deal with Genentech to identify and prioritize drug targets for treatment of immune disorders, the companies said last week.
As part of the multi-year collaboration, Phenomix will receive an upfront payment and an equity investment, as well as research funding and future milestone payments on products emerging from the collaboration. Phenomix will also retain rights to develop products based on certain targets discovered by the companies, Phenomix said.
MultiCell Technologies Raises $2M in Private Financing; Introduces New Website
MultiCell Technologies said last week that it has raised $2 million in a private placement consisting of convertible stock and warrants with institutional investors.
MultiCell said it plans to use the proceeds for general corporate purposes, including investment in research and development, and strengthening its balance sheet to enhance its image among strategic partners, customers, and vendors.
Ascendiant Securities served as placement agent on the transaction.
The company has also launched a new website that better represents the company’s structure and technology focus.
The new website, which is also expected to facilitate access to information by investors and other interested parties, can be accessed at the new address, http://www.multicelltech.com.
MultiCell provides hepatic cells and cell lines to pharmaceutical companies for induction studies and toxicity screening in drug discovery.
Beckman Coulter to Discuss Q2 Financial Results
Beckman Coulter will host a conference call on Monday, July 26 at 9:30 am EDT to discuss the company’s second quarter ended June 30. BC will release its earnings earlier that same morning.
The call will be hosted by John Wareham, chairman and CEO, Scott Garrett, president and chief operating officer, and James Glover, vice president and chief financial officer. Interested parties can find further details or access a live webcast of the call by going to the investor relations portion of the company’s website, http://www.beckmancoulter.com.
Xenogen Announces IPO
Xenogen last week announced the initial public offering of 4,200,000 shares of common stock at a price of $7 per share.
The company has also granted underwriters an option to purchase an additional 630,000 shares to cover over-allotments, if any, the company said. Xenogen will be listed on NASDAQ under the symbol “XGEN.”
Xenogen markets real-time in vivo, small-animal imaging instruments, software, and reagents for academic and pharmaceutical drug discovery.
Life Sciences Insights to Cover Technology Vendors in Q3 2004
Life Sciences Insights, a subsidiary of IDC, said last week that it would add in-depth coverage of life science technology companies to its market sizing, forecasting, and industry analysis programs.
Companies that Life Sciences Insights plans on covering include GE Medical Systems, Applied Biosystems, Agilent Technologies, Thermo Electron, Invitrogen, PerkinElmer, Bio-Rad Laboratories, Waters, MDL, Accelrys, and Tripos.
Founded in January 2004, Life Sciences Insights provides market research, analysis, and consulting services to customers in the life sciences industry.